A claim that LL-37 is “resistance-proof” needs more evidence than its origin in human host defense. Bacterial susceptibility can depend on surface structures and environmental conditions. One primary study illustrates why a result against a named organism should not be treated as a universal property of every strain or clinical infection.
The phosphorylcholine experiment
A 2000 study investigated phosphorylcholine on the surface of Haemophilus influenzae and susceptibility to LL-37/hCAP18. Bacteria expressing that surface feature survived peptide exposure better under the tested conditions. The effect depended on factors including salt conditions and environmental choline. This was a mechanistic susceptibility study, not evidence about an LL-37 treatment course in patients.
The result matters because it challenges an overly simple division between natural peptides and medicines to which microbes can adapt. It does not show that all organisms use the same mechanism. Nor does it establish a clinical resistance rate, a recommended combination treatment or a way to predict a patient’s response from the organism’s name alone.
Distinguish the experiment’s questions
| Question | What would answer it? |
|---|---|
| Can a surface feature affect killing? | A controlled mechanistic experiment. |
| How common is that feature? | Appropriate sampling and characterization. |
| Does it change patient outcomes? | Clinical research with relevant treatment and follow-up. |
| Does a medicine overcome it? | A separate tested intervention, rather than an assumption. |
An experiment answering the first question should not be cited as though it answered all four. A large difference in laboratory survival can be biologically important while remaining an uncertain guide to human treatment. Preserve both parts of that interpretation.
Read broad-spectrum claims critically
Ask whether the source tested one strain or many, which conditions were used and what counted as inhibition or killing. A list of organisms assembled from different papers can hide substantial differences in experimental methods. It also does not establish activity against an unidentified cause of a person’s symptoms.
For a clinical infection, diagnosis and treatment selection require appropriate professional assessment. This susceptibility research does not justify replacing prescribed therapy or attempting to adjust an experimental peptide exposure. Its practical value is a better question: what human evidence shows that the actual proposed preparation works for this organism and clinical condition? Without that link, “resistance-proof” remains an unsupported treatment claim.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.